The results of the presented experiments herein may be of clinical interest especially in view of that FDA-approved GLP-1 analogues, such as exenatide and liraglutide, are approved for the treatment of diabetes type II and thus tentatively could be used as novel treatments of nicotine addiction. The gene discussed is GLP1R; the disease is nicotine dependence.